@misc{indiciaeb8a5e006643a,
  title = {OKN4395, a first-in-class EP2/EP4/DP1 triple antagonist reprograms prostanoid-driven immunosuppression to restore antitumor immunity},
  author = {Grandclaudon, M. and Boulch, M. and Thaller, A. and Sabio-Ortiz, J. and Grimaldi, A. and Goxe, M. and Knopf, A. and Daugan, M. V. and Huehn, E. and Gnerre, C. and Jeay, S. and Faronato, M. and Dakhli, H. and Lopez-Lastra, S. and Hardy, A. and Sanchez, S. and Mayer, I. and Hoste, R. and Montanari, F. and Soumelis, V. and Alberti, J. and Pattarini, L. and Hoffmann, C. and Pierce, A. J.},
  year = {2026},
  doi = {10.64898/2026.02.08.704632},
  url = {https://www.biorxiv.org/content/10.64898/2026.02.08.704632v1},
  note = {Source identifier: 10.64898/2026.02.08.704632}
}